[Progress in the application of silk fibroin in tissue engineered drug delivery system].

Szczegóły
Abstrakt

Tytuł:: [Progress in the application of silk fibroin in tissue engineered drug delivery system].
Autorzy:: Li S; The Second Clinical Medical College of Lanzhou University, Lanzhou Gansu, 730000, P.R.China.; Department of Orthopaedics, the 940 Hospital of PLA Joint Logistics Support Force, Lanzhou Gansu, 730050, P.R.China.
Shi X; Department of Orthopaedics, the 940 Hospital of PLA Joint Logistics Support Force, Lanzhou Gansu, 730050, P.R.China.
Xu B; The Second Clinical Medical College of Lanzhou University, Lanzhou Gansu, 730000, P.R.China.; Department of Orthopaedics, the 940 Hospital of PLA Joint Logistics Support Force, Lanzhou Gansu, 730050, P.R.China.
Zhen P; Department of Orthopaedics, the 940 Hospital of PLA Joint Logistics Support Force, Lanzhou Gansu, 730050, P.R.China.
Li S; Department of Orthopaedics, the 940 Hospital of PLA Joint Logistics Support Force, Lanzhou Gansu, 730050, P.R.China.
Źródło:: Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery [Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi] 2021 Sep 15; Vol. 35 (9), pp. 1192-1199.
Typ publikacji:: Journal Article
Język:: Chinese
Imprint Name(s):: Publication: Chengdu Shi : Hua xi yi ke da xue Fu shu di 1 yi yuan
Original Publication: Chengdu Shi : Hua xi yi ke da xue Fu shu di 1 yi yuan,
MeSH Terms:: Fibroins*
Nanofibers*
Drug Carriers ; Drug Delivery Systems ; Silk ; Tissue Engineering
References:: Acta Biomater. 2020 Oct 15;116:223-245. (PMID: 32889111)
Mater Sci Eng C Mater Biol Appl. 2019 Jun;99:129-139. (PMID: 30889664)
Colloids Surf B Biointerfaces. 2019 Aug 1;180:118-126. (PMID: 31035055)
J Biomater Sci Polym Ed. 2019 Apr;30(6):462-485. (PMID: 30755095)
Chem Soc Rev. 2018 Aug 28;47(17):6486-6504. (PMID: 29938722)
Int J Nanomedicine. 2017 Sep 11;12:6721-6733. (PMID: 28932116)
Biomaterials. 2017 Aug;136:67-85. (PMID: 28521202)
Theranostics. 2019 Jun 9;9(15):4525-4541. (PMID: 31285777)
Colloids Surf B Biointerfaces. 2018 Mar 1;163:369-378. (PMID: 29335199)
Nanomedicine. 2016 Jul;12(5):1193-204. (PMID: 26772428)
J Colloid Interface Sci. 2016 Jun 15;472:16-33. (PMID: 26998786)
Int J Nanomedicine. 2019 Feb 22;14:1451-1467. (PMID: 30863071)
J Mater Chem B. 2021 Feb 15;9(5):1238-1258. (PMID: 33406183)
Int J Nanomedicine. 2019 Jun 07;14:4261-4276. (PMID: 31289441)
J Mater Chem B. 2019 Nov 14;7(42):6592-6603. (PMID: 31589221)
Acta Biomater. 2017 Jan 15;48:157-174. (PMID: 27746359)
J Control Release. 2019 May 10;301:129-139. (PMID: 30880079)
Colloids Surf B Biointerfaces. 2019 Jan 1;173:689-697. (PMID: 30384265)
J Biomed Mater Res A. 2018 Apr;106(4):1092-1103. (PMID: 29210169)
J Colloid Interface Sci. 2021 Jul;593:142-151. (PMID: 33744525)
Eur J Pharm Biopharm. 2018 Dec;133:176-187. (PMID: 30291964)
Int J Biol Macromol. 2020 Nov 15;163:2145-2161. (PMID: 32950527)
J Biomed Mater Res A. 2018 Aug;106(8):2158-2170. (PMID: 29577604)
Int J Biol Macromol. 2018 Oct 15;118(Pt A):775-782. (PMID: 29959009)
Biomaterials. 2016 Nov;106:205-16. (PMID: 27566869)
Int J Nanomedicine. 2017 Oct 19;12:7721-7735. (PMID: 29089766)
Acta Biomater. 2019 Jun;91:60-71. (PMID: 30986530)
J Control Release. 2020 May 10;321:324-347. (PMID: 32061791)
Tissue Eng Regen Med. 2018 Jan 16;15(2):131-143. (PMID: 30603541)
Biomaterials. 2016 Mar;83:233-48. (PMID: 26774562)
Acta Biomater. 2016 Mar 1;32:178-189. (PMID: 26766632)
Colloids Surf B Biointerfaces. 2019 Mar 1;175:636-643. (PMID: 30583219)
Contributed Indexing:: Keywords: Silk fibroin; sustained drug release; tissue engineering
Local Abstract: [Publisher, Chinese] 综述不同类型丝素蛋白（silk fibroin，SF）载药缓释载体的性能、特性以及对装载药物的释放行为影响，并对 SF 载药缓释载体目前在组织工程药物缓释系统中存在的问题与发展前景进行讨论。. [Publisher, Chinese] 广泛查阅近年关于 SF 载药缓释载体的文献，从缓释载体类型、药物释放特性、适用范围、存在的优点及不足、解决办法等方面进行总结分析。. [Publisher, Chinese] 目前制备的 SF 载药缓释载体主要分为 SF 微颗粒、SF 支架、SF 膜、SF 水凝胶、SF 纳米纤维、SF 海绵等；各类型 SF 载药缓释载体有各自优点及存在的问题，其中最突出问题是药物初期突释现象，通过改善制备工艺、调整材料配比参数等可有效解决药物初期突释。通过联合使用多种不同材料可制备出不同类型复合载药缓释载体，实现不同条件下的适用范围及不同的药物释放行为。. [Publisher, Chinese] SF 是组织工程良好的药物载体，通过改进制备工艺、改变材料结构等方式可解决药物初期突释问题；通过对多种类型 SF 载药缓释载体优点进行结合，有望制备出符合不同临床需要的 SF 载药缓释载体。.
Substance Nomenclature:: 0 (Drug Carriers)
0 (Silk)
9007-76-5 (Fibroins)
Entry Date(s):: Date Created: 20210915 Date Completed: 20210916 Latest Revision: 20220426
Update Code:: 20240105
PubMed Central ID:: PMC8444144
DOI:: 10.7507/1002-1892.202103066
PMID:: 34523288
: Czasopismo naukowe

Objective: The properties and characteristics of different types of silk fibroin (SF) drug-loaded sustained-release carriers and their effects on the drug release behavior were reviewed, and the existing problems and development prospects of SF drug-loaded sustained-release carriers in tissue engineering drug delivery system were discussed.
Methods: The literatures about drug-loaded SF sustained-release carriers in recent years were extensively consulted, and the types of sustained-release carriers, characteristics of drug release, range of applications, advantages and disadvantages, and solutions were summarized and analyzed.
Results: At present, the SF drug-loaded sustained-release carriers are mainly divided into SF microparticles, SF scaffolds, SF membranes, SF hydrogels, SF nanofibers, SF sponges, and so on. These types of SF drug-loaded sustained-release carriers have their own advantages and problems, of which the most prominent problem is the burst release of drugs at the initial stage. While, the initial burst release of drugs can be effectively solved by improving the preparation process and adjusting the material ratio. Different types of drug-loaded sustained-release carriers can be prepared by combining different materials to achieve different application scopes and drug release behaviors under different conditions.
Conclusion: SF is a good drug-loaded carrier for tissue engineering, the burst release of drugs at the initial stage can be solved by improving the preparation process and changing the material structure; through the combination of the advantages of various types of SF drug-loaded sustained-release carriers, it is expected to prepare SF drug-loaded sustained-release carriers that meet different clinical needs.

Informacja